ARTICLE | Clinical News
Cometriq cabozantinib regulatory update
March 31, 2014 7:00 AM UTC
The European Commission conditionally approved an MAA for Cometriq cabozantinib from Exelixis to treat progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Exelixi...